Evaluation of nCoV-QS (MiCo BioMed) for RT-qPCR detection of SARS-CoV-2

from nasopharyngeal samples using CDC FDA EUA qPCR kit as a gold standard:

an example of the need of validation studies.

Byron Freire-Paspuel¹, Patricio Vega-Mariño², Alberto Velez², Paulina Castillo², Marilyn Cruz²

and Miguel Angel Garcia-Bereguiain¹.

1. One Health Research Group. Universidad de Las Américas. Quito. Ecuador

2. Agencia de Regulación y Control de la Bioseguridad y Cuarentena para Galápagos. Puerto

Ayora. Ecuador.

#corresponding author: Miguel Angel Garcia-Bereguiain (magbereguiain@gmail.com).

Running Head: Comparison of MiCo BioMed and CDC qPCR kits for SARS-CoV-2.

Abstract. Background. Several qPCR kits are available for SARS-CoV-2 diagnosis, mostly lacking

of evaluation due to covid19 emergency. Objective. We evaluated nCoV-QS (MiCo BioMed) kit

using CDC kit as gold standard. Results. We found limitations for nCoV-QS: 1) lower sensitivity 2)

lack of RNA quality control probe 3) no capacity to quantify viral load. Conclussions. Validation

studies should be implemented for any SARS-CoV-2 RT-qPCR commercial kit to prevent

unreliable diagnosis.

Background.

Multiple in vitro RT-qPCR diagnosis kits are available on the market for for the detection of SARS-CoV-2. Some of them have received emergency use authorization (EUA) from the U.S. Food & Drug Administration (FDA) while others only report validations made by manufacturers, and in general little is known about their performances using clinical specimens. The CDC designed 2019-nCoV CDC EUA kit (IDT, USA) is based on N1 and N2 probes to detect SARS-CoV-2 that have received positive evaluation on recent reports (1-3), and and RdRP as an RNA extraction quality control. Other kit avalaible in the market is nCoV-QS (MiCo BioMed; South Corea) that include probes "ORF3a" and "N" probes for SARS-CoV-2 detection but no probe for

Objective.

RNA extraction quality control (4).

This study compared the performance in terms of positive percent agreement (PPA) of nCoV-QS (MiCo BioMed; South Corea) and 2019-nCoV CDC EUA kit (IDT, USA) primers and probes for SARS-CoV-2 qPCR diagnosis from nasopharyngeal samples.

Study design.

Fiftyfour (54) clinical specimens (nasopharyngeal swabs collected on 0.5mL TE pH 8 buffer) from patients selected as suspicious for SARS-CoV-2 infection were included on this study during the surveillance in Galapagos Islands started on April 8th 2020. Also, six negative controls (TE pH 8 buffer) were included as control for carryover contamination. Both CoV-QS and 2019-nCoV CDC EUA kits were kindly granted by independent donors to be used at SARS-CoV-2 diagnosis laboratory "LabGal" at "Agencia de Regulacion y Control de la Bioseguridad y Cuarentena para Galapagos" at Puerto Ayora in Galapagos Islands (Ecuador), where we

2

considered this validation necessary to guarantee the sensibility of SARS-CoV-2 during the surveillance.

Results.

Twenty-five (25) samples were tested following an adapted version of the CDC protocol (1) using CFX96 BioRad instrument and PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) as an alternate RNA extraction method, and also interpreting as positive 3 samples where a probe was positive with Ct<40 and the second one with Ct values up to 41.15 (See Table 1 and 2a). We performed this protocol for both nCoV-QS and 2019-nCoV CDC EUA primers and probes kits. Nine samples were negative for both kits; Sixteen samples were positive for 2019-nCoV CDC EUA (range of Ct values: 23.02-41.15 for N1; 24.08-40.12 for N2), but only ten (PPA 62.5%; p<0.001) of those ones were positive for nCoV-QS (range of Ct values: 28.71-39.98 for ORF3a; 24.48-35.44 for N). Results are detailed on Table 1a. The assay was validated to detect 20 viral RNA copies/uL by using 2019-nCoV N positive control (IDT, USA).

Twenty-nine (29) samples were tested following instructions manual from MiCo BioMed for nCoV-QS kit (4), using MiCo BioMed One RT-qPCR kit. PureLink Viral RNA/DNA Mini Kit (Invitrogen, USA) was used for RNA extraction. We performed this protocol for both nCoV-QS and 2019-nCoV CDC EUA primers and probes kits. Twelve samples were negative for both kits; Seventeen samples were positive for 2019-nCoV CDC EUA (range of Ct values: 23.1-39.05 for N1; 22.96-38.8 for N2), but only 12 (PPA 70.5%; p<0.001) of those ones were positive for nCoV-QS (range of Ct values: 26.45-39.43 for ORF3a; 24.03-39.89 for N). Results are detailed on Table 1 and 2b. We used CFX96 BioRad to run qPCR but also results were confirmed using Veri-Q PCR316 instrument from MiCo BioMed (4). The assay sensitivity indicated on manufacturers

3

manual (1.8 copies/uL for OFR3a and 4.24 copies/uL for N) could not be validated because

positive control concentration was not provided.

In summary, overall PPA for nCoV-QS was 66.7% (22 out of 33 positives samples for 2019-nCoV

CDC EUA; p<0.001), and 70.5% and 62.5% for MiCo BioMed and adapted CDC protocols,

respectively. Additionally, considering the viral loads calculated following adapted CDC protocol

with 2019-nCoV N positive control (IDT, USA), the limit of detection (viral copies/uL) for nCoV-

QS kit is much higher than the one indicated at manufacturer's manual (4).

Discussion

Although the main limitation of our study is the sample size (54 specimens), our results support

that nCoV-QS kit had a significant lower performance in terms on PPA and sensitivity compared

to 2019-nCoV CDC EUA. Also, the lack of any probe for RNA extraction quality control like RdRP

and the unreported concentration of positive controls provided for the kit that does not allow

viral load calculations, are limitations to be considered when using nCoV-QS kit.

Considering the worldwide high demand of reagents for SARS-CoV RT-qPCR diagnosis, supplies

shortage is a fact, actually affecting harder to developing countries like Ecuador. Under this

scenario, validation studies are helpful to guarantee the quality of the supplies in the market for

every country in the world.

Ethical considerations

All samples have been submitted for routine patient care and diagnostics. Ethical approval for

this study was not required since all activities are according to legal provisions defined by the

"Comité de Operaciones Especiales Regional de Galápagos" that is leading the Covid19

suerveillance in Galapagos Islands. Written informed consent has been obtained by each

4

patient. All data used in the current study was anonymized prior to being obtained by the

authors.

Funding.

None.

Authorship contribution statement.

All authors contributed to study conceptualization, experimental procedures and revision and

approval of final version of the manuscript.

Byron Freire-Paspuel and Miguel Angel García Bereguiain analyzed the data and wrote the

manuscript.

Declaration of Competing Interest.

All authors have no conflict of interest to declare.

Acknowledgements.

We thank the medical personnel from "Ministerio de Salud Pública" at Galapagos Islands and

the staff from the "Agencia de Regulación y Control de la Bioseguridad y Cuarentena para

Galápagos" for their support. We also thank Dr. Ronald Cedeño from OPS/WHO for his work

during Covid 19 surveillance in Galapagos Islands. We specially thank Gabriel Iturralde, Oscar

Espinosa and Dr Tannya Lozada from "Dirección General de Investigación de la Universidad de

Las Américas" for logistic support to make SARS-CoV-2 diagnosis possible in Galapagos Islands.

References.

1. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for

5

Coronavirus Disease 2019 (COVID-19). Center for Diseases Control and Prevention, USA.

https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html (last access 04/20/20).

- 2. Daniel D. Rhoads, Sree S. Cherian, Katharine Roman, Lisa M. Stempak, Christine L. Schmotzer, Navid Sadri. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. Accepted Manuscript Posted Online 17 April 2020.

 J. Clin. Microbiol. doi:10.1128/JCM.00760-20.
- 3. Arun K. Nallaa, Amanda M. Castob, Meei-Li W. Huanga, Garrett A. Perchettia, Reigran Sampoleoa, Lasata Shresthaa, Yulun Weia, Haiying Zhua, Keith R. Jeromea, Alexander L. Greningera. Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit. Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit. JCM Accepted Manuscript Posted Online 8 April 2020. J. Clin. Microbiol. doi:10.1128/JCM.00557-20
- 4. file:///Users/magb/Downloads/EN%20Inserts-Veri-

Q%20PCR%20316%20Coronavirus%20disease%202019COVID-19%20Detection%20Kit.pdf

Table 1. Performance of nCoV-QS compared to 2019-nCoV CDC EUA for RT-qPCR SARS-CoV-2 diagnosis (% values: PPA).

	CDC Probes SARS CoV-2 Positive	CDC Probes SARS CoV-2 Negative
Veri-Q Probes SARS CoV-2 Positive	22 (66.7%)	0
Veri-Q Probes SARS CoV-2 Negative	11	21

Table 2. Ct values for nCoV-QS and 2019-nCoV CDC EUA RT-qPCR using CDC adapted protocol for 25 samples (a) and MiCoBioMed protocol for 29 samples (b).

Sample	Conc.	CT (2019-nCoV CDC EUA)		Result (2019-nCoV CDC	CT (nCoV-QS)		Result (nCoV-	
	[copies/µL]	N1	N2	RP	EUA)	ORF3a	N	QS)
1	193453,3	23,02	24,8	25,04	Positive	28,72	24,48	Positive
2	151418,7	23,34	25,16	22,69	Positive	32,19	24,63	Positive
3	28204,0	25,53	28,02	26,11	Positive	30,78	27,3	Positive
4	7157,3	27,31	29,82	25,43	Positive	34,76	30,31	Positive
5	699,3	30,34	33,23	25,32	Positive	37,29	32,25	Positive
6	684,1	30,37	33,3	25,29	Positive	N/A	33,58	Positive
7	657,4	30,42	32,37	29,23	Positive	38,26	32,16	Positive
8	261,6	31,62	33,76	27,32	Positive	39,88	33,67	Positive
9	236,5	31,75	34,4	21,73	Positive	39,98	34,24	Positive
10	162,4	32,24	34,87	23,17	Positive	30,04	35,44	Positive
11	15,2	35,33	37,47	26,37	Positive	N/A	N/A	Negative
12	9,0	36,01	40,09	24,87	Positive	N/A	N/A	Negative
13	2,8	37,53	39,62	25,27	Positive	N/A	N/A	Negative
14	1,7	38,2	40,12	26,97	Positive	N/A	N/A	Negative
15	1,2	38,58	39,99	27,74	Positive	N/A	N/A	Negative
16	0,2	41,15	39,51	27,98	Positive	N/A	N/A	Negative
17	N/A	N/A	N/A	23,11	Negative	N/A	N/A	Negative
18	N/A	N/A	N/A	26,6	Negative	N/A	N/A	Negative
19	N/A	N/A	N/A	25,56	Negative	N/A	N/A	Negative
20	N/A	N/A	N/A	25,12	Negative	N/A	N/A	Negative
21	N/A	N/A	N/A	25,26	Negative	N/A	N/A	Negative
22	N/A	N/A	N/A	27,63	Negative	N/A	N/A	Negative
23	N/A	N/A	N/A	26,35	Negative	N/A	N/A	Negative
24	N/A	N/A	N/A	25,6	Negative	N/A	N/A	Negative
25	N/A	N/A	N/A	27,77	Negative	N/A	N/A	Negative

		N1	N2	RP		ORF3a	N	
1	883226,7	23,1	22,96	24,14	Positive	27,11	24,03	Positive
2	736560,0	23,31	23,39	27,04	Positive	27,51	24,39	Positive
3	153530,7	25,07	24,97	28,66	Positive	29,16	26,22	Positive
4	23205,6	27,2	27,48	27,63	Positive	31,22	28,19	Positive
5	4244,5	29,11	29,2	27,07	Positive	33,65	29,76	Positive
6	1886,7	30,02	30,88	29,81	Positive	34,23	30,84	Positive
7	1706,6	30,15	30,17	32,26	Positive	32,02	30,46	Positive
8	1573,9	30,13	30,12	31,17	Positive	32,26	30,53	Positive
9	719,5	31,1	31,2	26,25	Positive	35,4	31,03	Positive
10	176,0	32,69	32,77	24,04	Positive	26,45	31,87	Positive
11	143,5	32,8	32,36	31,46	Positive	35,09	32,81	Positive
12	51,6	34,07	34,51	26,56	Positive	39,43	39,89	Positive
13	40,3	34,35	35,39	24,38	Positive	N/A	N/A	Negative
14	3,3	37,17	37,43	26,51	Positive	N/A	N/A	Negative
15	1,8	37,87	38,27	30,89	Positive	N/A	N/A	Negative
16	1,6	37,63	37,62	29,84	Positive	N/A	N/A	Negative
17	0,6	39,05	38,8	27,27	Positive	N/A	N/A	Negative
18	N/A	N/A	N/A	28,25	Negative	N/A	N/A	Negative
19	N/A	N/A	N/A	27,07	Negative	N/A	N/A	Negative
20	N/A	N/A	N/A	30,45	Negative	N/A	N/A	Negative
21	N/A	N/A	N/A	30,65	Negative	N/A	N/A	Negative
22	N/A	N/A	N/A	27,92	Negative	N/A	N/A	Negative
23	N/A	N/A	N/A	29,59	Negative	N/A	N/A	Negative
24	N/A	N/A	N/A	29,09	Negative	N/A	N/A	Negative
25	N/A	N/A	N/A	30,16	Negative	N/A	N/A	Negative
26	N/A	N/A	N/A	30,19	Negative	N/A	N/A	Negative
27	N/A	N/A	N/A	30,76	Negative	N/A	N/A	Negative
28	N/A	N/A	N/A	31,06	Negative	N/A	N/A	Negative
29	N/A	N/A	N/A	33,76	Negative	N/A	N/A	Negative